PDGFRA and gastrointestinal stromal tumor: Taken together, all of these findings show that there is growing evidence in favor of the marked immunogenicity of PDGFRA-mutant GIST, likely specific of D842V mutants only, providing a possible proof of principle for testing immune-therapeutic approaches in this subset of GIST patients, which remains poor in terms of therapeutic options [39,40].